Galileo Cosmos – a powerful tool in life science data analytics
In Life Sciences analytics you have lots of data and you’re already answering lots of questions. What about the questions you’re not asking? Spending millions of dollars on data to answer specific questions leaves you with a lot of data and a lot of additional questions – Galileo Cosmos helps you find the critical additional questions and answers that will add value to your business.
Life sciences analytics is all about patient flow – moving through treatment protocols for a specific disease, being managed from drug to drug to improve outcomes, managing new diseases as comorbidities develop.
Using conventional analytic approaches, conducting a patient flow analysis is cumbersome, time consuming and often confined by the constraints of the analysis. With Galileo Cosmos you can complete multiple patient flow analyses across large and small patient groups using different flow parameters – all in minutes instead of days.
The benefits of Galileo Cosmos in flow analysis:
- Speed – even with millions of patients a flow analysis will be completed in a few minutes
- Flexibility – testing flow characteristics using different competitive product sets is as easy as a drag-and-drop selection process
- Detailed output – all stages of flow are quantified by time as well as patient count
- Multiple cohorts – any number of different cohort definitions can be used so that you can test how these factors affect the flow results
Sophisticated patient flow is a core capability of Galileo Cosmos. Using EHR and/or claims data, Galileo Cosmos gives you the most powerful patient flow analysis available.
Better Targeting through Segmentation and Cohort Design
In Life Sciences analytics we live and die by the reliability of our patient segmentation. Some call it cohort definition, but it is the same thing – a group of patients sharing similar characteristics that can be targeted for research or marketing purposes.
There are three types of patient cohort:
- Defined Cohort – based on known or expected characteristics, typically used in clinical trial design
- Behavioural cohort – based on characteristics that are expected such as response / non-response to drug therapy
- Discovered cohort – identified through data exploration not normally conducted using traditional methods
Life sciences analytics have always been good at answering the first two cohort types; Galileo Cosmos is specifically designed to challenge the third – the discovered cohort. Multiple case studies have now demonstrated the value of Cosmos in identifying and quantifying these previously unknown cohorts, generating significant value in research, clinical trials and commercial settings.
Better understanding of the Complex Patient Journey
The days of managing patients as simple entities are over. We must find ways to manage the reality that patients are more complex.
- Patients have multiple conditions and their treatment overlaps
- Patients are seen by different types of healthcare professional whose roles interact
- Patients are treated with multiple drugs and other therapies that must be tracked and measured
Patients are very complex and the data available to help us better understand them are also becoming more complex.
- We need to analyse prescribing data alongside compliance and persistence data
- Diagnostic test data help us to better understand Population Health statistics
- “Omix” data can now be integrated to add layers of granularity to analysis
Galileo Cosmos was designed to meet these needs. Cosmos has a number of capabilities that are particularly well suited to the needs analysing more complex patients:
- Multi-source data combination
- Flexibility of approach with link analysis as well as statistics, combined with complex variable creation
- Comprehensive management of temporal elements in the analysis
- patient treatment flow
- diagnostic sequencing effects
These features allow us to:
- define the characteristics of the complex patient
- identify details of the multi-channel management of the patients
- quantify opportunities for improved care, whether procedural or drug related
Galileo Cosmos opens the window on understanding complex patients.